FRI, NOV 17 2023-theGBJournal|Fidson Healthcare Plc (Fidson) and Jiangsu Aidea Pharmaceutical Co., Ltd (Aidea Pharma), officially signed a strategic cooperation agreement in Yangzhou, China.
The agreement aims to promote and address medical challenges through the use of innovative drugs especially in the treatment of over 1.9 million HIV-infected people in Nigeria.
The two companies agreed to share and combine their respective resources, technical expertise and positions in the market to collaborate on project development, market expansion, and other aspects by integrating their competitive advantages in the pharmaceutical field.
Both companies will engage in multi-level and multi-form cooperation, including but not limited to product manufacturing, promotions and sales, and clinical research, involving existing products and pipeline projects.
“This collaboration marks an important step for Aidea Pharma in its commitment to global medical cooperation. By integrating our expertise and experience in the field of innovative drugs, we are confident in bringing greater well-being to African patients,” said Dr. Heliang Fu, Chairman of Aidea Pharma, at the agreement signing ceremony.
The collaboration holds promise as a significant growth driver for both companies, particularly as a major factor in the development of local pharmaceutical manufacturing in Nigeria.
It will also improve the healthcare and medical practice on the continent. It is expected to be a sterling example of in-depth cooperation in the medical field between China and Nigeria.
“We are eagerly looking forward to this collaboration and we believe that the complementary strengths of both parties will inject new vitality into the medical field in Africa. This is also in line with our commitment “To provide better and more accessible medicines for the
people of Africa,” Dr. Fidelis A. Ayebae, Managing Director and CEO of Fidson said.
Fidson is the largest and most influential pharmaceutical company in Nigeria. The company was the first to manufacture anti-retroviral ARV drugs in sub-Saharan Africa in 2005.
Aidea Pharma, is a research and development pharmaceutical company in China, focused on building a complete pipeline of anti-retroviral drug (ARV)and has core technical advantages and product first-mover advantages in this field.
The company aims to provide patients with a more diverse range of drug choices, continuously meeting the urgent needs for the upgrading of HIV treatment in China and strives to become a leader in the field of HIV treatment
X-@theGBJournal|Facebook-the Government and Business Journal|email:gbj@govbusinessjournal.com| govandbusinessj@gmail.com
